GeneDx Appoints Lisa Gurry as Chief Business Officer

GeneDx appointed Lisa Gurry as Chief Business Officer (CBO), effective immediately. In this newly-created role, Gurry will lead GeneDx’s next phase of transformation, advancing data and information services across biopharma, health systems, and other partners to accelerate the long-term vision of enabling precision medicine.

As Chief Business Officer, Gurry will architect and operate GeneDx’s strategic business operations and partnership models that open doors and create opportunities to unlock the full potential of GeneDx Infinity, a large rare disease dataset, with nearly one million exomes and genomes paired with over seven million phenotypic datapoints. 

GeneDx Infinity is already powering faster and more accurate diagnoses for families and enabling biopharma partners to accelerate drug discovery and development. Gurry will also oversee communications for GeneDx and partner on market growth strategies.

With deep expertise at the intersection of healthcare, technology, and data, Gurry brings a proven track record of turning bold ideas into scaled businesses. She co-founded Truveta, where she built the growth engine that helped to deliver strategic partnerships with over 100 organizations across life sciences, healthcare, public health, and academic research. 

Before Truveta, Gurry spent over two decades at Microsoft driving global growth strategies for Windows, Office, and Xbox.

“As the largest provider of rare disease diagnosis in the world, GeneDx is uniquely positioned to enable drug discovery and development, fueling the future of precision medicine with the most enriched genomic insights. As we enter our next phase of growth, Lisa’s world-class leadership in data commercialization, partnerships, and go-to-market execution is exactly what we need to unlock the full potential of genomic data,” said Katherine Stueland, President and CEO of GeneDx. “With the power of GeneDx Infinity, Lisa will help us drive value and better patient outcomes by delivering genomic insights across health systems and biopharma.”